Treatment of pemphigus beyond rituximab: chimeric autoantibody receptor T cell (CAAR-T cell) therapy

Pemphigus vulgaris is a rare, life-threatening, autoimmune bullous disease. After decades of systemic corticosteroids and corticosteroid-sparing immunosuppressants being used to control the disease, efficacy rituximab has been shown in randomized controlled studies. Hence constitutes first-line treatment for mild moderate-to-severe pemphigus according most recent European S2K guideline. Despite promising results with rituximab, there still no disease-specific available. In that regard, chimeric autoantibody receptor therapy (CAAR-T cell therapy) under spotlight utilizing cutting-edge technology.